Pathogenesis

Cleveland Clinic is a nonprofit multi-specialty academic medical center that integrates clinical and hospital care with research and education. Located in Cleveland, Ohio, it was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. U.S. News & World Report consistently names Cleveland Clinic as one of the nation’s best hospitals in its annual “America’s Best Hospitals” survey. In 2018, there were 7.9 million total outpatient visits, 238,000 hospital admissions and observations, and 220,000 surgical cases throughout Cleveland Clinic’s health system. Patients came for treatment from every state and 185 countries. Its research facilities encompass over 700,000 sq ft of laboratory space on campus with nearly 2,000 researchers and support personnel and an annual research budget exceeding $300 million.  Lerner Research Institute (LRI) is home to basic, translational, and clinical research at Cleveland Clinic. With its level of funding from federal and, non-federal sources, the LRI ranks in the top 10 Institutes in the country in terms of research success.  Its 30-year history of groundbreaking advances in antiviral innate immunity research makes Cleveland Clinic an internationally recognized institution in this area of research. These advances include many fundamental discoveries on interferon signal transduction and antiviral pathways. Among the members of the GVN center will be leading investigators in viral-host interactions, encompassing antiviral drug development, immune modulatory therapies, and emerging viral pathogens. The center also includes the recently established Florida Research and Innovation Center (FRIC) in Port Saint Lucie, Florida, dedicated to the advancement of innovative translational research focused on immuno-oncology and infectious diseases.

The Centre de Recerca en Sanitat Animal (CReSA) is the animal health research program of the Institut de Recerca i Tecnologia Agroalimentàries (IRTA), a public company of the Autonomous Government of Catalonia (Spain). CReSA is located at the campus of the Universitat Autònoma de Barcelona (UAB), working in a new and technologically advanced building with conventional laboratories as well as biocontainment with level-3 biosecurity (BSL3) laboratories and animal facilities. The mission of CReSA is to contribute to the advancement of scientific and technical knowledge on animal health by means of research, knowledge transfer and services to public and private bodies. The long term objective is to globally improve all aspects of animal health that influence the agri-food sector and public health. CReSA researchers’ expertise includes pathology, immunology, bacteriology, virology, entomology, epidemiology and molecular biology, as well as disease animal models. Viral research is focused on endemic and exotic viruses affecting mainly livestock (swine, ruminants and poultry) and occasionally wildlife. Zoonotic viruses including animal influenza viruses, West Nile virus, Rift Valley fever virus and MERS-coronavirus are nowadays significant poles of research.

The Microbiology, Immunology and Pathology (MIP) Department is comprised of over 400 individuals who share a common passion for solving some of the most important human and animal health problems today. Research programs include those related to mycobacteria, retroviruses, prions, and arthropod-borne infectious diseases, as well as the diagnostic investigation of naturally-occurring animal diseases. A leader in education, MIP provides the only microbiology undergraduate degree program in Colorado, a graduate program that provides training in a number of cutting-edge disciplines, and several specialized veterinary residency training programs.

Virology and immunology research at Gladstone is focused primarily on three primary and urgent challenges in HIV/AIDS. We desperately need a vaccine for those at risk of coming in contact with the virus, as well as a cure for the millions of people who are already infected. And finally, we need new approaches for restoring a normal lifespan to those who are HIV-positive—but dying much too early from diseases of aging. In addition to HIV, we’re working on a variety of other areas of investigation: Gladstone scientists are looking for new biological targets for drugs that will attack the hepatitis C virus—which has infected 170 million people worldwide. Hepatitis C is a common co-infection with HIV/AIDS. We are also investigating the molecular structure of viruses associated with cancer—and how to remove them from the body as a way to reduce the risk of cancer. And we are investigating why newborns and infants mount less effective immune responses to viruses than adults do.

The Institute of Human Virology (IHV) is the first center in the United States – perhaps the world – to combine the disciplines of basic science, epidemiology and clinical research in a concerted effort to speed the discovery of diagnostics and therapeutics for a wide variety of chronic and deadly viral and immune disorders – most notably HIV, the cause of AIDS. Formed in 1996 as a partnership between the State of Maryland, the City of Baltimore, the University System of Maryland and the University of Maryland Medical System, IHV is an institute of the University of Maryland School of Medicine and is home to some of the most globally-recognized and world-renowned experts in the field of human virology.

Karolinska Institute (KI) is one of the world’s leading medical universities. Their mission is centered toward research and education, to help improve people’s health. In Sweden, Karolinska Institute accounts for over 40 per cent of the medical academic research and has the largest collection of medical education. Since 1901 the Nobel Assembly at Karolinska Institute has selected the Nobel laureates in Physiology or Medicine, and several alumni have won the prestigious award.

The MRC-University of Glasgow Centre for Virus Research (CVR) represents the UK’s largest grouping of human and veterinary virologists. More than 20 principal investigators and their associated teams make up the research core of the CVR creating a critical mass of researchers dedicated to the study of human and animal viral diseases. We carry out multidisciplinary research on viruses and viral diseases, translating the knowledge gained for the improvement of health and benefit of society. Research at the CVR spans molecular, structural and cellular levels through to the individual host and affected population, thus integrating molecular and structural virology, cell biology, pathogenesis, epidemiology and mathematical modelling. Our research covers emerging viruses including arboviruses, innate and intrinsic immunity to virus infection, hepatitis C virus, viruses and cancer, structural virology, viral genomics and bioinformatics.

Originally founded in 1892, the National Institute of Infectious Diseases aims at carrying out extensive and original research projects on a variety of contagious diseases from the standpoint of preventive medicine, improving human health and welfare by suppressing infectious diseases, and clarifying and supporting the scientific background of health and medical administration of the government. These functions may be summarized into 1) research activities, 2) reference services for infectious diseases, 3) surveillance of infectious diseases, 4) national control tests and other tests, 5) international cooperation, and 6) training activities.

Finding solutions to prevent, treat and cure infectious diseases and understanding the complexities of microbes and the immune system requires innovative approaches and concentrated effort. This is why the University of Melbourne – a world leader in education, teaching and research excellence – and The Royal Melbourne Hospital – an internationally renowned institution providing outstanding care, research and learning –partnered to create the Peter Doherty Institute for Infection and Immunity (Doherty Institute); a centre of excellence where leading scientists and clinicians collaborate to improve human health globally.